On Tuesday, Krystal Biotech stock cleared an important technical benchmark, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 91, up from 88 the day before. The biotech stock will join the S&P 600 Index on June 24.
IBD's unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks matches up against other publicly traded companies.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating at the beginning of a new climb.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Krystal Biotech Stock A Buy?
Krystal Biotech stock is working on a consolidation with a 189.97 buy point. See if the biotech stock can break out in heavy trading. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech company posted 0% EPS growth in the latest quarterly report, while sales growth came in at 0%.
Krystal Biotech stock holds the No. 17 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and United Therapeutics are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
